For more than two decades naturally presented, human leukocyte antigen (HLA)-restricted
peptides (immunopeptidome) have been eluted and sequenced using liquid
chromatography-tandem mass spectrometry (LC-MS/MS). Since, identified disease-
associated HLA ligands have been characterized and evaluated as potential active
substances. Treatments based on HLA-presented peptides have shown promising results in
clinical application as personalized T cell-based immunotherapy. Peptide vaccination …